Long-term outcomes after transoral incisionless fundoplication in patients with GERD and LPR symptoms

Karim S Trad, Daniel G Turgeon, Emir Deljkich, Karim S Trad, Daniel G Turgeon, Emir Deljkich

Abstract

Background: A retrospective study evaluated safety, symptom resolution, patient satisfaction, and medication use 1-2 years after transoral incisionless fundoplication (TIF) in patients with gastroesophageal reflux disease (GERD) and/or laryngopharyngeal reflux (LPR) symptoms.

Methods: Thirty-four patients with a confirmed diagnosis of GERD symptoms that were inadequately controlled by antisecretory medications, and who where either dissatisfied with their current therapy or not willing to continue taking medication, underwent TIF using EsophyX at our community-based hospital. Follow-up assessments were completed in 28 patients.

Results: Median age of the study group was 57 (range = 23-77) years, BMI was 25.7 (18.3-36.4) kg/m(2), and 50% were female. All patients had documented chronic GERD for a median 5 (1-20) years and refractory symptoms to proton pump inhibitors (PPIs). Hiatal hernia was present in 75% (21/28) of patients, and 21% (6/28) had erosive esophagitis (LA grade A or B). TIF was performed following a standardized TIF-2 protocol and resulted in reducing hiatal hernia and restoring the natural anatomy of the gastroesophageal (GE) junction (Hill grade I). There were no postoperative complications. At a median 14-months follow-up, 82% (23/28) of patients were off daily PPIs (64% completely off PPIs), and 68% (19/28) were satisfied with their current health condition compared to 4% before TIF. Median GERD Health-Related Quality of Life scores were significantly reduced to 4 (0-25) from 26 (0-45) before TIF (P < 0.001). Heartburn was eliminated in 65% (17/26) and improved by >50% in 86% (24/28) of patients. Regurgitation was eliminated in 80% (16/20) of patients. Atypical LPR symptoms such as hoarseness, coughing, and throat clearing were eliminated in 63% (17/27) of patients as measured by Reflux Symptom Index scores.

Conclusion: Our results in 28 patients confirm the safety and effectiveness of TIF, documenting symptomatic improvement of GERD and LPR symptoms and clinically significant discontinuation of daily PPIs in 82% of patients.

Figures

Fig. 1
Fig. 1
Modified schematic drawings of the esophagogastric transoral incisionless fundoplication (TIF) technique with a depiction of fastener placement. A similar drawing was presented by Dr. Barnes and Dr. Hoddinott [15]
Fig. 2
Fig. 2
Percentage of patients (n = 13) with predominant troublesome atypical GERD symptoms as evaluated by RSI questionnaires before TIF on daily PPIs and at the median of 17 (range = 3–29) months follow-up after TIF. P < 0.02 in all cases with significant differences. Associations not statistically significant are indicated by * (two-tailed Fisher’s exact test)
Fig. 3
Fig. 3
Percentage of patients (n = 15) with predominant troublesome typical GERD symptoms as evaluated by GERD-HRQL questionnaires, before TIF on daily PPIs (87%) and at the median of 13 (range = 4–27) months follow-up after TIF. In all cases with significant differences, P < 0.005, except for **, where P = 0.04. Association not statistically significant is indicated by * (two-tailed Fisher’s exact test)
Fig. 4
Fig. 4
Percentage of patients (n = 28) with troublesome typical and atypical GERD symptoms as evaluated by GERSS questionnaires before TIF on PPIs and at the median of 14 (range = 3–29) months follow-up after TIF. *P < 0.005; **P = 0.05; ***P = 0.13 (two-tailed Fisher’s exact test)
Fig. 5
Fig. 5
Percentage of patients (n = 28) with troublesome atypical GERD symptoms before TIF on PPIs and at the median of 14 (range = 3–29) months follow-up after TIF. Symptom scores were obtained using RSI questionnaires. In all cases with significant differences, P ≤ 0.02, except for **, where P = 0.055 (approaching significance). Association not statistically significant is indicated by * (two-tailed Fisher’s exact test)
Fig. 6
Fig. 6
Bars represent number of patients on daily, occasionally, and completely off PPI therapy before and after TIF. Post-TIF, only 18% (5/28) of patients remained on daily PPIs at 14-months follow-up compared to 89% (25/28) before TIF; P < 0.001

References

    1. Dallemagne B, Weerts JM, Jehaes C, Markiewicz S, Lombard R. Laparoscopic Nissen fundoplication: preliminary report. Surg Laparosc Endosc. 1991;1(3):138–143.
    1. Tsimogiannis KE, Pappas-Gogos GK, Benetatos N, Tsironis D, Farantos C, Tsimoyiannis EC. Laparoscopic Nissen fundoplication combined with posterior gastropexy in surgical treatment of GERD. Surg Endosc. 2009;24:1303–1309. doi: 10.1007/s00464-009-0764-0.
    1. Finks JF, Wei Y, Birkmeyer JD. The rise and fall of antireflux surgery in the United States. Surg Endosc. 2006;20:1698–1701. doi: 10.1007/s00464-006-0042-3.
    1. Funch-Jensen P, Bendixen A, Iversen MG, Kehlet H. Complications and frequency of redo antireflux surgery in Denmark: a nationwide study, 1997–2005. Surg Endosc. 2008;22:627–630. doi: 10.1007/s00464-007-9705-y.
    1. Hahnloser D, Schumacher M, Cavin R, Cosendey B, Petropoulos P. Risk factors for complications of laparoscopic Nissen fundoplication. Surg Endosc. 2002;16:43–47. doi: 10.1007/s004640090119.
    1. Hunter JG, Swanstrom L, Waring JP. Dysphagia after laparoscopic antireflux surgery. The impact of operative technique. Ann Surg. 1996;224:51–57. doi: 10.1097/00000658-199607000-00008.
    1. Lundell L. Complications after anti-reflux surgery. Best Pract Res Clin Gastroenterol. 2004;18:935–945.
    1. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs. 2007;67:1521–1530. doi: 10.2165/00003495-200767110-00001.
    1. Lu M, Malladi V, Agha A, Abydayyeh S, Han C, Siepman N, Graham DY. Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. Dig Dis Sci. 2007;2052:2813–2820. doi: 10.1007/s10620-007-9811-7.
    1. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106(8):1419–1425. doi: 10.1038/ajg.2011.146.
    1. Locke GR, III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ., III Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456. doi: 10.1016/S0016-5085(97)70025-8.
    1. Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med. 1991;90:576–583.
    1. Madan AK, Ternovits CA, Tichansky DS. Emerging endoluminal therapies for gastroesophageal reflux disease: adverse events. Am J Surg. 2006;192:72–75. doi: 10.1016/j.amjsurg.2006.01.055.
    1. Bell RC, Freeman KD. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. Surg Endosc. 2011;25(6):1975–1984. doi: 10.1007/s00464-010-1497-9.
    1. Barnes WE, Hoddinott KM, Mundy S, Williams M. Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg Innov. 2011;18(2):119–129. doi: 10.1177/1553350610392067.
    1. American Society of General Surgeons (2009) ASGS Position Statement on Natural Orifice Surgery and Transoral Incisionless Fundoplication. Available at . Accessed 9 Aug 2011
    1. Society of American Gastrointestinal and Endoscopic Surgeons (2009) SAGES Position Statement on Endoluminal Therapies for Gastrointestinal Diseases. Available at . Accessed 9 Aug 2011
    1. Jobe BA, Kahrilas PJ, Vernon AH, Sandone C, Gopal DV, Swanstrom LL, Aye RW, Hill LD, Hunter JG. Endoscopic appraisal of the gastroesophageal valve after antireflux surgery. Am J Gastroenterol. 2004;99:233–243. doi: 10.1111/j.1572-0241.2004.04042.x.
    1. Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus. 2007;20:130–134. doi: 10.1111/j.1442-2050.2007.00658.x.
    1. Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg. 1996;183:217–224.
    1. Allen JC, Parameswaran K, Belda J, Anvari M. Reproducibility, validity, and responsiveness of a disease-specific symptom questionnaire for gastroesophageal reflux disease. Dis Esophagus. 2000;13:265–270. doi: 10.1046/j.1442-2050.2000.00129.x.
    1. Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, Goldsmith C. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up. Surg Innov. 2006;13:238–249. doi: 10.1177/1553350606296389.
    1. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI) J Voice. 2002;16(2):274–279. doi: 10.1016/S0892-1997(02)00097-8.
    1. Cadiere GB, Buset M, Muls V, Rajan A, Rosch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Deviere J. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg. 2008;32:1676–1688. doi: 10.1007/s00268-008-9594-9.
    1. Cadiere GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication (TIF) using EsophyX. Surg Endosc. 2009;23:957–964. doi: 10.1007/s00464-009-0384-8.
    1. Hunter JG, Trus TL, Branum GD, Waring JP, Wood WC. A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. Ann Surg. 1996;223:673–685. doi: 10.1097/00000658-199606000-00006.
    1. Sala E, Salminen P, Simberg S, Koskenvuo J, Ovaska J. Laryngopharyngeal reflux disease treated with laparoscopic fundoplication. Dig Dis Sci. 2008;53:2397–2404. doi: 10.1007/s10620-007-0169-7.
    1. Walker SJ, Holt S, Sanderson CJ, Stoddard CJ. Comparison of Nissen total and Lind partial transabdominal fundoplication in the treatment of gastro-oesophgeal reflux. Br J Surg. 1992;79:410–414. doi: 10.1002/bjs.1800790512.
    1. Westcott CJ, Hopkins MB, Bach K, Postma GN, Belafsky PC, Koufman JA. Fundoplication for laryngopharyngeal reflux disease. J Am Coll Surg. 2004;199:23–30. doi: 10.1016/j.jamcollsurg.2004.03.022.
    1. Jobe BA, O’Rourke RW, McMahon BP, Gravesen F, Lorenzo C, Hunter JG, Bronner M, Kraemer SJ. Transoral endoscopic fundoplication in the treatment of gastroesophageal reflux disease: the anatomic and physiologic basis for reconstruction of the esophagogastric junction using a novel device. Ann Surg. 2008;248:69–76. doi: 10.1097/SLA.0b013e31817c9630.
    1. Patti MG, Arcerito M, Tamburini A, Diener U, Feo CV, Safadi B, Fisichella P, Way LW. Effect of laparoscopic fundoplication on gastroesophageal reflux disease-induced respiratory symptoms. J Gastrointest Surg. 2000;4:143–149. doi: 10.1016/S1091-255X(00)80050-5.
    1. So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998;124:28–32. doi: 10.1016/S0039-6060(98)70071-6.
    1. Wetscher GJ, Glaser K, Hinder RA, Perdikis G, Klingler P, Bammer T, Wieschemeyer T, Schwab G, Klingler A, Pointner R. Respiratory symptoms in patients with gastroesophageal reflux disease following medical therapy and following antireflux surgery. Am J Surg. 1997;174:639–643. doi: 10.1016/S0002-9610(97)00180-3.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe